Cannasouth Ltd
NZX:CBD
Cannasouth Ltd
NZX:CBD
Price:
0.098
NZD
Market Closed
Market Cap:
NZ$32.4m
Relative Value
There is not enough data to reliably calculate the relative value of CBD.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
CBD
Relative Value
Base Case
Not Available
Multiples Across Competitors
CBD Competitors Multiples
Cannasouth Ltd Competitors
Cannasouth Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| NZ |
|
Cannasouth Ltd
NZX:CBD
|
32.4m NZD | 33.9 | -3.7 | -4 | -4 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
947B USD | 14.6 | 46 | 31 | 33.1 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
584.8B USD | 6.2 | 21.8 | 15.2 | 18.6 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
268.2B CHF | 4.3 | 20.8 | 12.2 | 13.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
227.5B GBP | 5.2 | 29.8 | 16.5 | 23.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
233.8B CHF | 5.4 | 21.6 | 13.4 | 17.2 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
292.5B USD | 4.5 | 16.1 | 10 | 12.2 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 344.9 | 865 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.6 | 10.8 | 8 | 9.3 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
152.5B USD | 2.4 | 19.7 | 7.6 | 10.1 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
121.5B USD | 2.5 | 17.2 | 7.2 | 8.9 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
